Autopsy report · NCT00165373

rhEndostatin Protein Involving Pediatric Patients With Cancer

“Lack of drug supply”

The sponsor’s own words in the registry.

Life of this trial

• Registered 2 years 8 months after it had already started.
• Ran for about 2 years before it stopped.
• 21 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 1

Sponsor

Dana-Farber Cancer Institute

Sponsor type

University, hospital or other

Conditions

Solid Tumors

Interventions

rhEndostatin

Participants

21

Sites

1

Countries

United States

Trials that died the same way

• Sipuleucel-T, CT-011, and Cyclophosphamide for Advanced Prostate Cancer
  “Drug supply issues” (83% match in meaning)
• Effects of Antrodia Cinnamomea on the Hepatoma Patients After Transcatheter Hepatic Artery Chemoembolization
  “poor accrual and insufficient drug supply” (83% match in meaning)
• Treatment of Cancer-Related Bone Pain by Using Bone-Targeted Radiation-Based Therapy (Sn-117m-DTPA) in Patients With Prostate Cancer That Has Spread to Bones
  “Insufficient drug supply” (82% match in meaning)
• A Study of Panobinostat in Pediatric Patients With Solid Tumors Including MRT/ATRT
  “Drug supply” (76% match in meaning)
• MG1-MAGEA3 With Ad-MAGEA3 and Pembrolizumab in Patients With Previously Treated Metastatic Melanoma or Cutaneous Squamous Cell Carcinoma
  “insufficient suitable drug supply” (76% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.